共 50 条
- [21] Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases [J]. Digestive Diseases and Sciences, 2019, 64 : 3674 - 3675
- [22] Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 (09): : 1190 - 1201
- [23] Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab [J]. Digestive Diseases and Sciences, 2017, 62 : 1590 - 1596
- [25] Effect of obesity on vedolizumab response in inflammatory bowel disease [J]. ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 275 - 280
- [26] EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S704
- [27] Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I522 - I522
- [28] Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I283 - I283
- [29] Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study [J]. ANNALS OF GASTROENTEROLOGY, 2023, 36 (04): : 430 - 436
- [30] Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S451 - S452